Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Jianpeng Cao *Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, People's Republic of China.
Zhanliang Sun *Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, People's Republic of China.
Zhijun Zhou *Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, People's Republic of China.
Yilin HuangDepartment of Nuclear Medicine, Chongqing University Cancer Hospital, Chongqing, China.
Dengsai PengDepartment of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, People's Republic of China.
Xue JiangDepartment of Nuclear Medicine, Second Affiliated Hospital of Chengdu Medical College (China National Nuclear Corporation 416 Hospital), Chengdu, 610000, People's Republic of China.
Yue ChenDepartment of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, People's Republic of China. chenyue5523@126.com.
Funding
Isotope and Drug Innovation Fund of the National Engineering Research Center TWSCX-2023-CXJJ-07-1National Natural Science Foundation of China U20A20384Science and Technology Fund of Chengdu Medical College CYZYB22-19Sichuan Provincial Radiotherapy and Therapy Clinical Medicine Research Center Open Project 2024ZX07
6 · The paper itself
Abstract
Small-molecule inhibitors targeting prostate-specific membrane antigen (PSMA) have demonstrated promising results in the theranostics of prostate cancer (PCa). We designed and synthesized a novel small-molecule PSMA inhibitor, SC691. This study aimed to conduct a preliminary clinical prospective investigation of
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Preliminary clinical study of p-iodo benzoyl moiety-modified PSMA inhibitors and prospective comparison with 68Ga-PSMA-11. · full record | OpenQuestion